Skip to Content

Vassiliki A. Papadimitrakopoulou, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Jay and Lori Eisenberg Distinguished Professorship, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Vassiliki Papadimitrakopoulou is a Professor of Medicine in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. Her areas of expertise include design and development of novel therapeutic clinical trials for lung and head and neck neoplasms, personalized-genomics-driven lung cancer therapy and translational research and cancer chemoprevention. Her extensive experience in design, development and implementation of translational research in the context of multidisciplinary research teams has led to research funding from NCI, ASCO, and DOD both independently and as a member of a research team. She has prevention studies that have resulted in a series of innovative findings regarding the role of cyclin D1 overexpression and gene polymorphisms and the significance of aneuploidy as predictor and a tool for selecting high-risk cohorts for intervention and personalized targeted therapy approaches (EPOC trial). Her sustained contributions to the Head and Neck SPORE program with a series of innovative approaches have resulted in better understanding of the field and complemented a very well established research program at MD Anderson Cancer Center.

Currently, she serves as the principal investigator and leads numerous clinical and translational research projects with a focus on the development of biomarker-based targeted therapy to overcome therapeutic resistance in advanced disease.  Most notably she created and led the multidisciplinary clinical and translational research infrastructure dedicated to the treatment of metastatic refractory NSCLC as part of  the BATTLE-2 program,  designed and developed the first-in-the-world comprehensive genomics-driven umbrella approach in Squamous Lung Cancer, the Lung Master protocol, jointly sponsored by NCI-CTEP and FNIH/industry.  This work will change how we treat squamous lung cancer and has the greatest potential for bringing personalizing medicine to patients with this disease.  She is the Co-PI of an R01 Grant focusing on the role of KRAS mutations and targeting in lung cancer and leading numerous immunotherapy clinical trials. Dr. Papadimitrakopoulou is the lead author or co-author of over 175 published articles, book chapters, reviews and abstracts involving cancer therapeutics, prevention, and translational research and she has received several awards including the ASCO Young Investigator and Career Development Award.

Education & Training

Degree-Granting Education

1988 University of Patras School of Medicine, Patras, Greece, MD, Medicine

Postgraduate Training

1994-1997 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1991-1994 Clinical Residency, Internal Medicine, Columbia Presbyterian Medical Center, New York City
1990-1991 Clinical Residency, Institut Gustave Roussy, Paris, France
1989-1990 Clinical Internship, Metaxas Cancer Hospital, Piraeus, Greece

Board Certifications

1997 Internal Medicine, Medical Oncology
1994 Internal Medicine


Administrative Appointments/Responsibilities

Section Chief, Thoracic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015-present

Institutional Committee Activities

Member, IASLC Publications Committee, 2015-present
Member, Study Section Institutional Research Grant Program Committee (IRG), 2014-present
Member, Institutional Review Board, 2014-present
Member, Investigational New Drug Committee, 2012-present
Chair, Thoracic Cancer Multidisciplinary Program, 2011-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y, Byers L, Wang J, Papadimitrakopoulou V, Behrens C, Wistuba I. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research. In Press.
2. Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences 7(2):1-30, 10/2015.
3. Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP-framework, overview, and design principles. Chin Clin Oncol 4(3):36, 9/2015. PMID: 26408303.
4. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 8/2015. e-Pub 6/11/2015. PMCID: PMC4527963.
5. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 26(7):1476-80, 7/2015. e-Pub 5/29/2015. PMID: 26025965.
6. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther 97(5):488-91, 5/2015. e-Pub 2/10/2015. PMID: 25676724.
7. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21(7):1514-24, 4/1/2015. e-Pub 2/13/2015. PMID: 25680375.
8. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372(18):1700-9, 4/30/2015. PMID: 25923550.
9. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. Clin Cancer Res 21(4):739-48, 2/15/2015. e-Pub 12/16/2014. PMCID: PMC4335074.
10. Massarelli E, Papadimitrakopoulou V. Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer. Clin Cancer Res 21(4):670-4, 2/15/2015. e-Pub 1/6/2015. PMID: 25564153.
11. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Mitchell FT, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar A, Lee JJ, Myers JN, Issa JJ, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila), 2015. e-Pub 9/2015. PMID: 26342026.
12. Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck 36(11):1547-54, 11/2014. e-Pub 3/20/2014. PMCID: PMC4010580.
13. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. e-Pub 10/29/2014. PMCID: PMC4414661.
14. Hutcheson KA, Lewin JS, Holsinger FC, Steinhaus G, Lisec A, Barringer DA, Lin HY, Villalobos S, Garden AS, Papadimitrakopoulou V, Kies MS. Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. Head Neck 36(4):474-80, 4/2014. e-Pub 6/18/2013. PMCID: PMC4034517.
15. Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N, Dimitrijevic S, Urva S, Pylvaenaeinen I, Petrovic K, Johnson BE. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol 25(2):505-11, 2/2014. e-Pub 12/23/2013. PMID: 24368401.
16. Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Invest New Drugs 32(1):123-34, 2/2014. e-Pub 4/12/2013. PMID: 23579358.
17. Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, Soria JC, Gogov S, Miller N, Jehl V, Johnson BE. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol 25(2):409-15, 2/2014. e-Pub 12/23/2013. PMID: 24368400.
18. Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, Heymach JV, Blumenschein G, Cox JD, Hofstetter W, Fang B, Fossella F, Glisson B, Hong WK, Gold K, Johnson F, Kies MS, Liao Z, Lin S,. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncology 15(1):e42-50, 1/2014.
19. Dimou A, Papadimitrakopoulou V. Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med 4(3):386-401, 2014. e-Pub 6/30/2014. PMCID: PMC4263964.
20. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-47, 9/1/2013. PMID: 23920393.
21. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase I dose escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19(13):3671-3680, 7/1/2013. e-Pub 6/11/2013. PMID: 23757357.
22. Tsao AS, Papadimitrakopoulou V. The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non-Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clin Lung Cancer 14(4):311-21, 7/2013. e-Pub 4/11/2013. PMID: 23582282.
23. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 80(3):235-41, 6/2013. e-Pub 2/26/2013. PMID: 23485129.
24. William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8(2):222-8, 2/2013. e-Pub 1/2/2013. PMCID: PMC3549050.
25. Massarelli E, Papadimitrakopoulou VA. Phosphatidykinosital 3-kinase and Mammalian target of rapamycin pathway in non-small-cell lung cancer. J Thorac Oncol 7(16 Suppl 5):S379-82, 12/2012. PMID: 23160325.
26. Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small cell lung cancer: A phase I trial. J Thorac Oncol 7(10):1594-601, 10/2012. PMID: 22968184.
27. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small cell lung cancer. J Thorac Oncol 7(8):1315-26, 8/2012. e-Pub 5/2012. PMID: 22648207.
28. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2/8/2012. e-Pub 1/13/2012. PMCID: PMC3274509.
29. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DS, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M.D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825-32, 2012. PMCID: PMCPMC3465940.
30. Papadimitrakopoulou V. Secondary therapeutic strategies for EGF receptor pathway inhibition in non-small cell lung cancer. Forum Clin Oncol 3(Spec Issue):45-50, 2012.
31. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trial of Imatinib Mesylate and Docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-11, 12/2011. e-Pub 9/2011. PMID: 21892101.
32. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 6/2011. e-Pub 1/22/2010. PMID: 20094773.
33. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discov 1(1):44-53, 6/2011. e-Pub 6/1/2011. PMCID: PMC4211116.
34. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 5/15/2011. e-Pub 11/29/2010. PMCID: PMC3117018.
35. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Vandetanib restores head and neck squamous cell carcinoma cell's sensitivity to Cisplatin and radiation in vivo ad in vitro. Clin Cancer Res 17(7):1815-27, 4/1/2011. e-Pub 2/24/2011. PMCID: PMC3074405.
36. Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression rofiling predicts the development of oral cancer. Cancer Prev Res (Phila) 4(2):218-29, 2/2011. PMCID: PMC3074595.
37. Benchekroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila Pa) 3(7):800-9, 7/2010. e-Pub 6/2010. PMCID: PMC2900459.
38. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.
39. Yildirim G, Morrison WH, Rosenthal DI, Sturgis EM, Papadimitrakopoulou VA, Schwartz DL, Garden AS. Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head Neck 32(4):473-80, 4/2010. e-Pub 8/2009. PMID: 19691110.
40. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results from a Phase II prospective trial. J Clin Oncol 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.
41. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5(11):e14124, 2010. e-Pub 11/29/2010. PMCID: PMC2993951.
42. Guo M, Sneige N, Patel S, Feng J, Papadimitrakopoulou V, Sturgis E, Etzel Z, Hong WK, Tsao A. HPV infection and oral cytological changes in patients with oropharyngeal squamous carcinoma and their sexual partners. Cancer Cytopath 118(5):349-50, 2010.
43. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa) 2(11):931-41, 11/2009. PMID: 19892663.
44. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer inpatients with leukoplakia. Clin Cancer Res 15(19):6284-91, 10/1/2009. e-Pub 9/22/2009. PMCID: PMC2756317.
45. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V. Efficacy of Everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20(10):1674-91, 10/2009. e-Pub 6/2009. PMID: 19549709.
46. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen ZG, Shin DM. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila Pa) 2(9):823-9, 9/2009. e-Pub 9/8/2009. PMCID: PMC2910364.
47. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27(4):599-604, 2/1/2009. e-Pub 12/15/2008. PMCID: PMC2645856.
48. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila Pa) 2(1):14-21, 1/2009. PMID: 19139013.
49. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High dose Fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2(1):22-6, 1/2009. PMID: 19139014.
50. O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588-95, 4/1/2008. e-Pub 3/10/2008. PMID: 18332470.
51. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized Phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095-101, 4/1/2008. PMID: 18381950.
52. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2/2008. e-Pub 10/25/2007. PMID: 17960324.
53. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60, 2008.
54. Bristol IJ, Ahamad A, Garden AS, Morrison WH, Hanna EY, Papadimitrakopoulou VA, Rosenthal DI, Ang KK. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys 68(3):719-30, 7/1/2007. PMID: 17543999.
55. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007.
56. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/1/2006. PMID: 16943532.
57. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol 1(7):749-51, 9/2006. PMID: 17409953.
58. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):441S-445S, 7/15/2006. PMID: 16857825.
59. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The Prognostic Role of Loss of Insulin-like Growth Factor-binding Protein-3 Expression in Head and Neck Carcinogenesis. Cancer Lett 239(1):136-43, 7/2006. e-Pub 9/2005. PMID: 16181731.
60. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 12(10):3109-14, 5/15/2006. PMID: 16707609.
61. Kelloff GJ. Lippman SM. Dannenberg AJ. Sigman CC. Pearce HL. Reid BJ. Szabo E. Jordan VC. Spitz MR. Mills GB. Papadimitrakopoulou VA. Lotan R. Aggarwal BB. Bresalier RS. Kim J. Arun B. Lu KH. Thomas ME. Rhodes HE. Brewer MA. Follen M. Shin DM. Parnes HL. Siegfried JM. Evans AA. Blot WJ. Chow WH. Blount PL. Maley CC. Wang KK. Lam S. Lee JJ. Dubinett SM. Engstrom PF. Meyskens FL Jr. O'Shaughnessy J. Hawk ET. Levin B. Nelson WG. Hong WK. AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12 (12):3661-97, 2006.
62. Lippman SM. Lee JJ. Martin JW. El-Naggar AK. Xu X. Shin DM. Thomas M. Mao L. Fritsche HA Jr. Zhou X. Papadimitrakopoulou V. Khuri FR. Tran H. Clayman GL. Hittelman WN. Hong WK. Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. [Clinical Trial, Phase II. Research Support, N.I.H., Extramural]. Clin Cancer Res 12:3109-14, 2006.
63. Gillenwater A. Papadimitrakopoulou V. Richards-Kortum R. Oral premalignancy: new methods of detection and treatment. Curr Oncol Reports:146-54, 2006.
64. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Patients with locally Advanced Squamous Cell Cancer of the Head and Neck. J Clin Oncol 24:4163-9, 2006.
65. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and MAP Kinase Pathways in Lung Cancer Therapy. J Thor Oncol 1 (7):749-51, 2006.
66. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104(11):2430-6, 12/1/2005. PMID: 16245318.
67. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 104 (11)(11):2449-56, 12/1/2005. PMID: 16258975.
68. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 11/1/2005. PMID: 16199307.
69. Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 103(5):952-9, 3/1/2005. PMID: 15666322.
70. Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin Cancer Res 11:4151-9, 2005. PMID: 15930851.
71. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V,. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung carcinoma. Cancer 104:561-9, 2005.
72. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou VA, Huang S, Hong WK. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 11 (16):6065-74, 2005.
73. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 4/1/2004. PMID: 15050312.
74. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer 100(5):991-8, 3/1/2004. PMID: 14983495.
75. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 10(5):1565-73, 3/1/2004. PMID: 15014005.
76. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Troung M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54:308-15, 2004. PMID: 15184994.
77. Mao L, Hong WK, Papadimitrakopoulou V. Focus on head and neck cancer. Cancer Cell 5:311-6, 2004.
78. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10:2968-76, 2004. PMID: 15131032.
79. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou V, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10:658-67, 2004. PMID: 14760089.
80. Glover K, Perez-Soler R, Papadimitrakopoulou V. Tynsive Kinase inhibitors in development for non-small cell lung cancer. Sem in Oncology 31:83-92, 2004.
81. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21(24):4546-52, 12/2003. e-Pub 11/2003. PMID: 14597742.
82. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Clayman G, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 98(10):2214-23, 11/15/2003. PMID: 14601092.
83. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 7/2003. PMID: 12886869.
84. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 7/2003. PMID: 14596703.
85. Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95(3):198-205, 2/2003. PMID: 12569141.
86. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 1/2003. PMID: 12538456.
87. Papadimitrakopoulou VA, Liu DD, Mao L, Shin DM, El-Naggar A, Ibarguen H, Lee JJ, Hong WK, Hittelman WN. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev 11(12):1605-10, 12/2002. PMID: 12496051.
88. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2):322-30, 7/15/2002. PMID: 12124833.
89. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 7/15/2002. PMID: 12124835.
90. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8(2):314-46, 2/2002. PMID: 11839647.
91. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-9, 1/2002. PMID: 11917284.
92. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 7(10):3127-34, 10/2001. PMID: 11595705.
93. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19(12):3010-7, 6/15/2001. PMID: 11408495.
94. Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91(7):1316-23, 4/1/2001. PMID: 11283932.
95. Soria JC, Izzo J, Mao L, Hong WK, Papadimitrakopoulou VA. [Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention]. Bull Cancer 88(4):351-61, 4/2001. PMID: 11371369.
96. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6(5):1702-10, 5/2000. PMID: 10815888.
97. Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst 92(1):69-73, 1/5/2000. PMID: 10620636.
98. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125(10):1083-9, 10/1999. PMID: 10522499.
99. Izzo JG, Papadimitrakopoulou VA, Li XQ, Ibarguen H, Lee JS, Ro JY, El-Naggar A, Hong WK, Hittelman WN. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 17(18):2313-22, 11/5/1998. PMID: 9811462.
100. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90(20):1545-51, 10/21/1998. PMID: 9790547.
101. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 16(4):1325-30, 4/1998. PMID: 9552033.
102. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L. Presence of multiple in contiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res 4(3):539-44, 3/1998. PMID: 9533520.
103. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Smith T, Pugh W, Ha CS, McLaughlin P, Callender D, Cox J, Cabanillas F. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Leuk Lymphoma 26(1-2):49-56, 6/1997. PMID: 9250787.
104. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14(15):1799-803, 4/17/1997. PMID: 9150385.
105. Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am 3(2):92-9, Mar-Apr, 3/1997. PMID: 9099459.
106. Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, Batsakis JG, Lippman SM. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 89(3):257-8, 2/5/1997. PMID: 9017007.
107. Sarris AH, Papadimitrakopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin’s lymphomas, Hodgkin’s disease, or lymphomatoid papulosis. Ann Oncology 8:S59-S63, 1997.
108. Sarris AH, Luthra R, Papadimitrakopoulou V, Waasdorp M, Dimopoulos M, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris S, Pugh WC. Rapid amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin’s lymphomas, Hodgkin’s disease, or lymphomatoid papulosis. Ann Oncology 8 (Suppl 2):S1-S5, 1997.
109. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 56(11):2519-21, 6/1/1996. PMID: 8653689.
110. Sarris AH, Luthra R, Papadimitrakopoulou V, Kimopoulos M, McBride JA, Cabanillas F, Morris S, Deisseroth A, Pugh WC. Amplification of genomic DNA-PCR technique demonstrates the presence of the t (2; 5) rearrangement in anaplastic large cell lymphoma but no other non-Hodgkin’s lymphomas; Hodgkin's disease or lymphomatoid papulosis. Blood 88:1771-1779, 1996.
111. Cvitkovic FB, Haie-Meder C, Papadimitrakopoulou V, Armand JP, Cioloca C, Maugis N, Constans JP. Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. J Neurooncol 15(1):9-17, 1/1993. PMID: 8384255.
112. Singh A, Dewi R, Bhalla K, Li QK, Acquaah-Mensah G, Ruiz C, Montal E, Sudini KR, Skoulidis F, Tong P, Diao L, Wang J, Wistuba II, Papadimitrakopoulou V, Heymach J, Boros LG, Gabrielson E, Carretero J, Wong K, Biswal S, Girnun G. De novo lipogenesis represents a therapeutic target in Kras mutant NSCLC. Cancer & Metabolism. Submitted.

Last updated: 5/4/2016